• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
Classification Nametest,prostate specific antigen,free,(noncomplexed) to distinguish prostate cancer from benign conditions
Generic Namefree psa
PMA NumberP980007
Supplement NumberS004
Date Received04/01/2004
Decision Date05/07/2004
Product Code
MTG[ Registered Establishments with MTG ]
Advisory Committee Immunology
Supplement Typereal-time process
Supplement Reason change design/components/specifications - other
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for addition of the architect free psa to the i2000sr platform, a member of the architect i2000 instrument family. The device, as modified, will be marketed under the trade name architect free psa and is indicated for the quantitative determination of free prostate specific antigen (psa) in human serum. The architect free psa is intended to be used in conjunction with the architect total psa assay in men aged 50 years or older with total psa values between 4 and 10 ng/ml and dre non-suspicious for cancer to determine the % free psa value. The architect % free psa value can be used as an aid in discriminating between prostate cancer and benign disease.